Pages that link to "Q55426854"

The following pages link to Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. (Q55426854):

Displaying 48 items.

• Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings (Q57025849) (← links)
• Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection (Q59350050) (← links)
• Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil (Q60046097) (← links)
• Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant (Q60958294) (← links)
• Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018 (Q61814195) (← links)
• Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons (Q61814222) (← links)
• In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors (Q61814450) (← links)
• Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy (Q63246314) (← links)
• Influenza virus polymerase inhibitors in clinical development (Q63976719) (← links)
• Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil (Q64065291) (← links)
• An Effective Neutralizing Antibody Against Influenza Virus H1N1 from Human B Cells (Q64095827) (← links)
• A Step Forward in the Treatment of Influenza (Q64136457) (← links)
• (Q64239050) (← links)
• Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. (Q64901554) (← links)
• Drugs for Influenza Treatment: Is There Significant News? (Q64907744) (← links)
• Influenza virus-related critical illness: prevention, diagnosis, treatment. (Q64936560) (← links)
• A Broad and Potent H1-Specific Human Monoclonal Antibody Produced in Plants Prevents Influenza Virus Infection and Transmission in Guinea Pigs (Q89552975) (← links)
• A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions (Q89654019) (← links)
• SPINT2 inhibits proteases involved in activation of both influenza viruses and metapneumoviruses (Q89709684) (← links)
• Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil (Q89739869) (← links)
• Next-generation direct-acting influenza therapeutics (Q89843860) (← links)
• Favipiravir, an anti-influenza drug against life-threatening RNA virus infections (Q89877245) (← links)
• Respiratory Barrier as a Safeguard and Regulator of Defense Against Influenza A Virus and Streptococcus pneumoniae (Q89965550) (← links)
• Brevilin A, a Sesquiterpene Lactone, Inhibits the Replication of Influenza A Virus In Vitro and In Vivo (Q89996561) (← links)
• Anthralin Suppresses the Proliferation of Influenza Virus by Inhibiting the Cap-Binding and Endonuclease Activity of Viral RNA Polymerase (Q90055058) (← links)
• Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes (Q90187064) (← links)
• A Dual-Functioning 5'-PPP-NS1shRNA that Activates a RIG-I Antiviral Pathway and Suppresses Influenza NS1 (Q90240753) (← links)
• Generation of neutralizing and non-neutralizing monoclonal antibodies against H7N9 influenza virus (Q90475352) (← links)
• A Quinolinone Compound Inhibiting the Oligomerization of Nucleoprotein of Influenza A Virus Prevents the Selection of Escape Mutants (Q90598908) (← links)
• Amide-containing α-hydroxytropolones as inhibitors of hepatitis B virus replication (Q90685524) (← links)
• Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility (Q90689822) (← links)
• Key Role of the Influenza A Virus PA Gene Segment in the Emergence of Pandemic Viruses (Q90736243) (← links)
• Current and future influenza vaccines (Q91259900) (← links)
• Molecular Dynamics Simulation reveals the mechanism by which the Influenza Cap-dependent Endonuclease acquires resistance against Baloxavir marboxil (Q91452095) (← links)
• Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets (Q91452510) (← links)
• Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1 (Q91735838) (← links)
• Characterization of swine-origin H1N1 canine influenza viruses (Q91742158) (← links)
• The evolution and genetic diversity of avian influenza A(H9N2) viruses in Cambodia, 2015 - 2016 (Q91800481) (← links)
• Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission (Q91958639) (← links)
• Emerging antiviral resistance (Q92133182) (← links)
• Genome-wide CRISPR screen identifies host dependency factors for influenza A virus infection (Q92527342) (← links)
• Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019 (Q92633011) (← links)
• Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model (Q92690560) (← links)
• Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019 (Q92768473) (← links)
• Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference (Q93028017) (← links)
• Aryl and Arylalkyl Substituted 3-Hydroxypyridin-2(1H)-ones: Synthesis and Evaluation as Inhibitors of Influenza A Endonuclease (Q93083055) (← links)
• Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial (Q96292673) (← links)
• Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies (Q98161899) (← links)